NEW
Font size
WorksheetsDay 1 ENT Flashback
Total questions: 15
Worksheet time: 9mins
Medications that were shown to be beneficial to patients with HFrEF may not have the same benefits for patients with HFpEF
YES
NO
MAY BE
I DON'T KNOW
In HF treatment landscape, which beta-blocker has no randomized clinical trial on its significant reduction in all-cause mortality?
Nebivolo
Carvedilol
Propranolol
Bisoprolol
The mortality rate for patients with chronic HF is as high as ______ at 5 years post-diagnosis
25%
50%
75%
90%
In ESC 2016 HF guideline, Sacubitril/valsartan was given a class ____ as recommendation to replaced ACEi to further reduce the risk of HF hospitalization and death in patients with HFrEF
1A
1B
2A
2B
In SOLVD-Treatment (1991): which medication showed significantly reduction in the risk of all-cause mortality in patients with HFrEF?
Ramipril
Enalapril
Perindopril
Lisinopril
Which of the following is NOT substrate of Neprilysin enzyme?
Endothelin
Bradykinin
Aldosterone
BNP
Natriuretic peptides are released in response to:
Salt and water retention
Release of norepinephrine
Increase in cardiac wall stress
Increase in heart rate
Which NYHA functional classification is this – “Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity results in HF symptoms”?
CLASS I
CLASS II
CLASS III
CLASS IV
What is the most common cause of HF with reduced EF?
Hypertension
Valve disease
Cardiomyopathies
Coronary artery disease
What is the proposed mechanism of Sac/Val in cardiac remodeling?
↑ BNP and ↓ RAAS effects on cardiac
↓ both BNP and RAAS effects on cardiac
↑ both BNP and RAAS effects on cardiac
↓ BNP and ↑ RAAS effects on cardiac
According to ESC guideline, to rule out non-acute setting HF, we need to have BNP level
of:
< 20 pg/mL
< 35 pg/mL
< 100 pg/mL
< 125 pg/mL
Please label the following diagram accordingly
A: Pulmonary valve; B: Aortic valve; C: Tricuspid valve; D: Mitral valve
A: Aortic valve; B: Pulmonary valve; C: Mitral valve; D: Tricuspid valve
A: Aortic valve; B: Pulmonary valve; C: Tricuspid valve; D: Mitral valve
A: Pulmonary valve; B: Aortic valve; C: Mitral valve; D: Tricuspid valve
What is condition ‘X’ as described in this graph?
Myocardial infarction
Acute decompensated heart failure
Mortality in HF
Diabetes Mellitus
ESC 2016: Which pharmacological treatment did not have class 1 recommendation indicated in patients with symptomatic HFrEF?
Enalapril
Entresto
Ivabradine
Epleronone
In the PARADIGM-HF trial with Sac/Val vs Enalapril in HFrEF, what was the RRR achieved in its primary endpoint of CV death or HF hospitalization?
21%
18%
20%
16%
